Neda Rajamand Ekberg1, Ulrik Bodholdt2, Andrei-Mircea Catarig3, Sergiu-Bogdan Catrina4, Katrine Grau5, Cecilia Nagorny Holmberg6, Boris Klanger7, Søren Tang Knudsen8. 1. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Academic Specialist Centre, Centre for Diabetes, Stockholm, Sweden. Electronic address: Neda.ekberg@ki.se. 2. Kastrup Doctors, Kastrupvej 326, 1.tv., DK-277 Kastrup, Denmark. Electronic address: ulrik@bodholdt.dk. 3. Novo Nordisk A/S, Vandtårnsvej 108-110, DK-2860 Søborg, Denmark. Electronic address: aicg@novonordisk.com. 4. Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Academic Specialist Centre, Centre for Diabetes, Stockholm, Sweden. Electronic address: Sergiu-bogdan.catrina@ki.se. 5. Novo Nordisk A/S, Vandtårnsvej 108-110, DK-2860 Søborg, Denmark. Electronic address: kgau@novonordisk.com. 6. Novo Nordisk A/S, Vandtårnsvej 108-110, DK-2860 Søborg, Denmark. Electronic address: ccnh@novonordisk.com. 7. LäkarGruppen, Källgatan 10, 722 11 Västerås, Sweden. Electronic address: boris.klanger@ptj.se. 8. Steno Diabetes Center Aarhus (SDCA), Aarhus University Hospital, Aarhus, Denmark. Electronic address: soerknud@rm.dk.
Abstract
AIMS: As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden. METHODS: SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician's discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS). RESULTS: Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were -1.2 [-1.3; -1.1]%-points (-13 [-14; -12] mmol/mol) and -5.4 [-6.0; -4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide. CONCLUSIONS: In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use. CLINICALTRIALS. GOV IDENTIFIER: NCT03648281.
AIMS: As part of the SURE programme, SURE Denmark/Sweden aimed to study the real-world use of once-weekly (OW) semaglutide in adults with type 2 diabetes (T2D) in Denmark/Sweden. METHODS: SURE Denmark/Sweden was an ∼30-week, prospective, multicentre, open-label, observational study, enrolling adults with T2D and ≥1 documented HbA1c value ≤12 weeks before initiating semaglutide at their physician's discretion. Primary (change in HbA1c) and secondary (including change in body weight, glycaemic and weight-loss target achievement) endpoints were assessed between baseline and end of study (EOS). RESULTS: Of the 331 patients initiating semaglutide, 282 (85%) completed the study on treatment. For the latter, estimated mean changes [95% confidence interval] in HbA1c and body weight between baseline and EOS were -1.2 [-1.3; -1.1]%-points (-13 [-14; -12] mmol/mol) and -5.4 [-6.0; -4.7] kg (both p < 0.0001), respectively, with similar results in Denmark and Sweden. At EOS, 67.5% of patients achieved HbA1c <7%; 49.4% achieved a weight reduction of ≥5%. Reported adverse events were consistent with the known safety profile of semaglutide. CONCLUSIONS: In routine clinical practice in Denmark/Sweden, use of OW semaglutide was associated with glycaemic and weight-loss benefits in a wide range of adults with T2D, supporting real-world use. CLINICALTRIALS. GOV IDENTIFIER: NCT03648281.
Authors: P Marzullo; T Daffara; C Mele; M Zavattaro; A Ferrero; M Caputo; F Prodam; G Aimaretti Journal: J Endocrinol Invest Date: 2022-04-16 Impact factor: 5.467
Authors: Maria Dolores Garcia de Lucas; Jose Pablo Miramontes-González; Beatriz Avilés-Bueno; Ana Isabel Jiménez-Millán; Francisco Rivas-Ruiz; Luis M Pérez-Belmonte Journal: Front Endocrinol (Lausanne) Date: 2022-09-16 Impact factor: 6.055
Authors: Monika Kellerer; Margit Staum Kaltoft; Jack Lawson; Lasse Lykke Nielsen; Krzysztof Strojek; Ömür Tabak; Stephan Jacob Journal: Diabetes Obes Metab Date: 2022-06-29 Impact factor: 6.408